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ABSTRACT
Aims Epithelial cell adhesion molecule (EpCAM) is a cell
surface protein with oncogenic features that is
expressed on healthy human epithelia and corresponding
malignant tumours. EpCAM expression frequently
correlates with more aggressive tumour behaviour and
new EpCAM-speciﬁc therapeutic agents have recently
been approved for clinical use in patients with cancer.
However, no consensus exists on how and when to
evaluate EpCAM expression in patients with cancer.
Material and methods EpCAM expression was
assessed by a well-established immunohistochemical
staining protocol in 2291 primary tumour tissues and in
108 metastases using the EpCAM-speciﬁc antibody
clone VU1D9. A total immunostaining score was
calculated as the product of a proportion score and an
intensity score. Four expression subgroups (no, weak,
moderate and intense) were deﬁned. As described
previously, the term ‘EpCAM overexpression’ was
reserved for tissues showing a total immunostaining
score >4.
Results EpCAM was highly expressed in most tumours
of gastrointestinal origin and in some carcinomas of the
genitourinary tract. However, hepatocellular carcinomas,
clear cell renal cell cancer, urothelial cancer and
squamous cell cancers were frequently EpCAM negative.
EpCAM expression in breast cancer depended on the
histological subtype; lobular histology usually showed no
or weak expression. Most metastases were EpCAM
positive and they frequently reﬂected the expression
phenotype of the primary tumour.
Conclusion EpCAM expression was detected on
adenocarcinomas of various primary sites. If EpCAM-
speciﬁc antibodies are intended to be used in patients
with cancer, we recommend prior immunohistochemical
evaluation of EpCAM expression, particularly in patients
with renal cell cancer, hepatocellular carcinoma,
urothelial carcinoma, breast cancer and squamous cell
carcinomas.
INTRODUCTION
Epithelial cell adhesion molecule (EpCAM; syn.
GA733-2, TACSTD1, KSA, EGP40, CD326, 17-1A,
HEA125, MK-1, EGP-2, EGP-34, ESA, KS1/4) is a
tumour-associated antigen that is expressed
in normal epithelia, with the exception of squa-
mous epithelia, epidermal keratinocytes, gastric
parietal cells, myoepithelial cells, thymic cortical
epithelium and hepatocytes.
1
Tumour tissues, such as primary and metastatic
breastcancer,frequentlyoverexpressEpCAM.
2Gastl
and colleagues observed EpCAM overexpression in
35.6% of patients with invasive breast cancer, and
thiswasassociatedwithpoordisease-freeandoverall
survival.
3 Moreover, our group has shown that
survival decreases signiﬁcantly with increasing
amounts of EpCAM expression.
4 EpCAM can be
usedasprognosticmarkerinnode-positiveandnode-
negative breast cancer.
5 Furthermore, frequent and
high-level EpCAM expression has been found in
adenocarcinomas of the colon, stomach, pancreas
and prostate.
6 Most soft-tissue tumours and all
lymphomas are EpCAM negative. EpCAM over-
expression has been associated with a dismal prog-
nosis in other tumour entities, such as gallbladder
cancer,
7 ovarian cancer
8 and pancreatic cancer.
9
Overexpression of EpCAM has been found to be
associated with enhanced transcription and trans-
lation of the proto-oncogene c-myc.
10 Recently, the
proteolytic cleavage of the intracellular domain of
EpCAM (EpICD) has been shown to confer
a mitogenic signal.
11 12 Furthermore, DNA meth-
ylation appears to be a potential mechanism for
regulation of EpCAM expression.
13
The observation of antigen overexpression on
carcinomas and its correlation with decreased
survival have promoted the EpCAM antigen to
a ‘druggable’ target for cancer treatment. Several
EpCAM-targeting immunotherapeutic approaches
are currently being tested in clinical trials.
11 The
ﬁrst monoclonal antibody applied for human cancer
therapy of gastrointestinal tumours was the
EpCAM-directed monoclonal antibody 17-1A.
14
Many years later in 2009, the ﬁrst anti-EpCAM
antibody, named catumaxomab,
15 was approved by
the European Commission for the treatment of
malignant ascites in cancer patients with EpCAM-
positive tumours. Catumaxomab showed a clear
clinical beneﬁt in patients with malignant ascites
secondary to epithelial cancers, with an acceptable
safety proﬁle.
16 Overall survival showed a positive
trend for the catumaxomab group, and in
a prospectively planned analysis it was signiﬁcantly
prolonged in patients with gastric cancer. Adeca-
tumumab (MT201) is a fully human monoclonal
anti-EpCAM antibody that mediates complement-
dependent and antibody-dependent cellular cyto-
toxicity. In patients with metastatic breast cancer,
this antibody showed dose-dependent and target-
dependent clinical activity and the occurrence of
new metastases was reduced.
17 A new bispeciﬁc
T-cell engager (BiTE) anti-EpCAM/CD3 antibody
has been shown to have signiﬁcant antitumour
activity in breast cancer and lung cancer mouse
models. The human surrogate MT110 is currently
in preclinical development.
18
So far, no consensus exists on which tumours
and methods should be used for testing EpCAM
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Original articleexpression. To help clinicians in their decision to select patients
for treatment with EpCAM-speciﬁc antibodies, EpCAM
expression was evaluated in the most frequent tumour entities
and metastases to determine the grade of expression and its
stability.
MATERIAL AND METHODS
Tumour samples
Primary tumour samples from 2291 patients with cancer, and
metastases from 108 patients with different tumour entities,
were assessed for EpCAM expression. Tumour tissues and
staining were in part obtained from previously published series.
Slides were obtained from either classical parafﬁn blocks or
tissue microarrays. Tissues were divided into ﬁve groups:
gastrointestinal cancers, genitourinary cancer, upper digestive
tract and respiratory tract cancers, breast cancer and metastases.
Parafﬁn blocks from two breast cancer cell line spheroids
(MCF-7 cells: EpCAM positive; Hs578Tcells: EpCAM negative)
were used as negative and positive controls. Parafﬁn blocks of
the two cell lines were prepared, and slides were cut for each
immunohistochemical run.
Slide preparation, deparafﬁnisation and rehydration
Sections (4 mm thick) from parafﬁn blocks were cut and
mounted onto adhesive-coated glass slides. Slides were placed in
a xylene bath and incubated for 5 min. The xylene in the baths
was changed, and the procedure was repeated twice. Slides were
then placed in absolute ethanol for 3 min, and this was repeated
once. Slides were then placed in 95% ethanol for 3 min, and this
was repeated once. Slides were ﬁnally placed in distilled water
for a minimum of 30 s.
Proteolytic digestion
Slides were placed in pronase (Dako Pronase, code no. S2013;
Dako, Glostrup, Denmark) and incubated for 20 min at 378C.
Slides were then placed in Tris-buffered saline (Dako TBS; code
no. S3001 or S1968).
Staining procedure using an automated system
Slides were placed into the Dako Autostainer Universal Staining
System and a speciﬁc programme for EpCAM immunostaining
consisted of the following steps: (1) endogenous peroxidase
blocking by treating slides with 3% hydrogen peroxide and
incubating for 5 min; (2) incubation with the primary antibody
(NCL-ESA, clone VU1D9, concentration 1:100; Novocastra,
Newcastle, UK) for 60 min; (3) incubation with the peroxidase-
labelled secondary antibody (Dako EnVision+, code no. K4000)
for 30 min; (4) incubation with the substrate-chromogen
3,39-diaminobenzidine tetrahydrochloride (Dako Liquid DAB+,
code no. K3467) for 8 min; (5) upon completion of the run, slides
were removed from the staining machine and rinsed in Dako
TBS; (6) slides were placed in a bath of aqueous haematoxylin
(code no. S3309) for 45 s; (7) slides were then gently rinsed in
a distilled water bath; (8) slides were dehydrated through the
following solutions: 95% ethanol over 3 min with one bath
change, 100% ethanol over 3 min with two bath changes, and
xylene over 5 min with two bath changes; (9) coverslips were
then applied to specimens using routine pathological procedures.
Immunohistochemical evaluation and statistical analysis
Antigen expression was deﬁned as speciﬁc when a staining signal
was present on the tumour cell membrane. Similar to the Allred
score in the evaluation of oestrogen receptor positivity,
19
EpCAM expression was evaluated by calculating a total immu-
nostaining score (TIS) as the product of a proportion score (PS)
and an intensity score (IS). The PS describes the estimated
fraction of positively stained tumour cells (0, none; 1, <10%; 2,
10e50%; 3, 51e80%; 4, >80%). The IS represents the estimated
staining intensity as compared with control cell lines (0, no
staining; 1, weak; 2, moderate; 3, strong). The TIS (TIS¼PS
3 IS) ranges from 0 to 12 with only nine possible values (that is,
0, 1, 2, 3, 4, 6, 8, 9 and 12). EpCAM ‘overexpression’ has been
deﬁned previously as a TIS >4.
3 Furthermore we deﬁned four
subgroups: no expression, TIS 0; weak expression, TIS 1e4;
moderate expression, TIS 6 and 8; intense expression, TIS 9 and
12. For correlation of EpCAM expression in primary tumours
and corresponding metastases, a regression analyses using the
SPSS software program for Windows (SPSS, Chicago, Illinois,
USA) was performed.
RESULTS
EpCAM expression in gastrointestinal cancers
Colorectal cancer showed the highest EpCAM expression overall
(table 1). From 104 adenocarcinoma tissue samples, 82% (n¼85)
showed intense expression (TIS 9 and 12) and 12% (n¼12)
showed moderate expression (TIS 6 and 8), accounting for an
overexpression rate of 94% (TIS >4; n¼97); only 6% (n¼7)
showed weak expression (TIS 1e4).
Ampullary cancer and gastric cancer showed overexpression
rates (TIS >4) of 85% (n¼29) and 74% (n¼54), respectively.
Oesophageal cancer showed an intense EpCAM expression in
39% (TIS 9 and 12; n¼17) and a moderate expression (TIS 6 and
8) in 26% (n¼11) of tumour samples (overexpression 65%;
TIS >4; n¼28). EpCAM negativity (TIS 0) was observed in 12%
Table 1 EpCAM expression in primary adenocarcinoma of the gastrointestinal tract
Tumour type (no. of samples)
No EpCAM overexpression* EpCAM overexpression*
No expression (TIS 0)
Weak expression
(TIS 1e4)
Moderate expression
(TIS 6, 8)
Intense expression
(TIS 9, 12)
n% n% n% n%
Colon cancer (104) 0 0 7 6 12 12 85 82
Ampullary cancer (34) 0 0 5 15 14 41 15 44
Gastric cancer (73) 3 4 16 22 14 19 40 55
Oesophageal cancer (43) 5 12 10 23 11 26 17 39
Gallbladder cancer (128) 9 7 34 27 53 41 32 25
Pancreatic cancer (203) 2 1 71 35 56 26 74 37
Hepatocellular carcinoma (47) 40 86 3 6 2 4 2 4
EpCAM expression was determined by immunohistochemistry.
*EpCAM overexpression deﬁned by Gastl et al
3.
EpCAM, epithelial cell adhesion molecule; TIS, total immunostaining score.
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tumour samples. Of 128 gallbladder samples, 7% were negative
(TIS 0; n¼9); EpCAM overexpression rate (TIS >4) was 66%
(n¼85), and 27% (n¼34) showed only weak expression (TIS
1e4). Hepatocellular carcinomas were predominantly EpCAM
negative. In fact, 86% (n¼40) of tumour samples were negative;
intense, moderate and weak expression was found in 6%, 4%
and 4% of cases, respectively.
EpCAM expression in breast cancer
In patients with breast cancer (table 2) EpCAM overexpression
(TIS >4) was observed in 46% (n¼87) of 188 samples with
invasive ductal carcinoma. By subgroup analysis, 19% (n¼35)
lacked EpCAM expression (TIS 0), 35% (n¼66) showed weak
expression (TIS 1e4), 20% (n¼37) stained moderately (TIS 6
and 8), and 26% (n¼50) exhibited intense EpCAM expression
(TIS 9 and 12).
In contrast, invasive lobular breast cancer showed lower
EpCAM expression scores. In these tumours, EpCAM over-
expression (TIS >4) was found in 15% (n¼12) of 82 samples. By
subgroup analysis, 41% (n¼34) were EpCAM negative (TIS 0),
44% (n¼36) showed weak expression (TIS 1e4), 11% (n¼9)
stained moderately (TIS 6 and 8), and 4% (n¼3) exhibited
intense EpCAM expression (TIS 9 and 12).
EpCAM expression in genitourinary cancers
Ovarian, endometrial and prostate cancers were observed to be
high EpCAM expressers, showing overexpression rates (TIS >4)
of 73% (n¼236), 88% (n¼62) and 89% (n¼96), respectively.
Moreover, weak EpCAM expression (TIS 1e4) was observed in
19% (n¼63), 6% (n¼4) and 10% (n¼11) of these tumours,
respectively. Of note, the expression of EpCAM in patients with
ovarian cancer depended on histology (table 3). In fact,
mucinous ovarian cancer had a lower EpCAM overexpression
rate (TIS >4; 55%, n¼32) as compared with serous, endome-
trioid or other histologies (TIS >4, 76%, n¼204). Furthermore,
in patients with renal cancer, EpCAM expression depended
strongly on the histological subtype. Clear cell renal cell cancers
were predominantly EpCAM negative (TIS 0). In fact, 79%
(n¼38) of these tumours were found to lack EpCAM expression.
Only 12% (n¼6) were found to display EpCAM overexpression
(TIS >4). Non-clear-cell renal cell cancer lacked EpCAM
expression (TIS 0) in 31% (n¼23) of cases. Weak (TIS 1e4) and
overexpression (TIS >4) were observed in 14% (n¼10) and 56%
(n¼41) of these tumours, respectively.
Fifty-nine per cent (n¼54) of squamous cell cancers of the
cervix, vagina and vulva were predominantly EpCAM negative
(TIS 0). EpCAM overexpression (TIS >4) and weak expression
(TIS 1e4) were observed in 26% (n¼24) and 15% (n¼14),
respectively. Finally, we observed EpCAM negativity (TIS 0)
in 56% (n¼51) of urothelial carcinomas, and an EpCAM
overexpression rate (TIS >4) of 27% (n¼25).
EpCAM expression in upper digestive, respiratory tract and
(neuro)endocrine cancers
We observed no signiﬁcant differences between non-small-cell
and small cell lung cancer (table 4). Both types were observed to
be high expressers, showing overexpression rates (TIS >4)
of 74% (n¼107) and 75% (n¼45), respectively. EpCAM expres-
sion lacked (TIS 0) in only 7% (n¼11) and 20% (n¼12),
respectively. Moreover, there was no signiﬁcant difference in
EpCAM expression between different histological subtypes of
Table 2 EpCAM expression in primary breast cancer
Tumour type (no. of samples)
No EpCAM overexpression* EpCAM overexpression*
No expression (TIS 0)
Weak expression
(TIS 1e4)
Moderate expression
(TIS 6, 8)
Intense expression
(TIS 9, 12)
n% n% n% n%
Invasive ductal breast cancer (188) 35 19 66 35 37 20 50 26
Invasive lobular breast cancer (82) 34 41 36 44 9 11 3 4
Other breast cancer histologies (107) 18 17 42 39 26 24 21 20
EpCAM expression was determined by immunohistochemistry.
*EpCAM overexpression deﬁned by Gastl et al
3.
EpCAM, epithelial cell adhesion molecule; TIS, total immunostaining score.
Table 3 EpCAM expression in genitourinary tract cancers
Tumour type (no. of samples)
No EpCAM overexpression* EpCAM overexpression*
No expression
(TIS 0)
Weak expression
(TIS 1e4)
Moderate expression
(TIS 6, 8)
Intense expression
(TIS 9, 12)
n% n% n % n %
Ovarian cancer (326) 27 8 63 19 100 31 136 42
Serous, endometrioid and other
histologies (268)
21 8 43 16 87 32 117 44
Mucinous histology (58) 6 10 20 35 13 22 19 33
Renal cancer (122) 61 50 14 12 15 12 32 26
Clear cell histology (48) 38 79 4 9 5 10 1 2
Non-clear-cell histology (74) 23 31 10 14 10 14 31 41
Urothelial cancer (91) 51 56 15 17 21 23 4 4
Endometrial cancer (70) 4 6 4 6 16 23 46 65
Prostate cancer (108) 1 1 11 10 35 32 61 57
SCC of the cervix, vagina and vulva (92) 54 59 14 15 13 14 11 12
EpCAM expression was determined by immunohistochemistry.
*EpCAM overexpression deﬁned by Gastl et al
3.
EpCAM, epithelial cell adhesion molecule; SCC, squamous cell cancer; TIS, total immunostaining score.
J Clin Pathol 2011;64:415e420. doi:10.1136/jcp.2011.090274 417
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(neuro)endocrine tumours. The overexpression rate (TIS >4) of
well-differentiated neuroendocrine tumours was 88% (n¼47).
The overexpression rate (TIS >4) of differentiated thyroid
cancer was 87% (n¼77). As observed for squamous cell cancers
from other origins, squamous cell cancers of the oral cavity
showed EpCAM negativity in 40% (n¼51) (TIS 0) or weak
expression in 38% (n¼48) (TIS 1e4).
EpCAM expression in metastases
In total, from 108 metastases that were stained for evaluation of
EpCAM expression, only 4% (n¼4) lacked EpCAM expression
(TIS 0; table 5). The expression phenotype of the metastases
usually reﬂects the expression of the primary tumour
(ﬁgure 1AeD). In fact, in lymph node metastases from patients
with colorectal cancer, 89% (n¼43) of samples were observed to
have EpCAM overexpression (TIS >4) and 10% (n¼5) showed
weak EpCAM expression (TIS 1e4). In line with these obser-
vations, 83% (n¼15) of colorectal cancer liver metastases were
EpCAM overexpressing (TIS >4) and 17% (n¼3) showed a weak
EpCAM expression (TIS 1e4). Peritoneal metastases from
different tumour origins were usually EpCAM positive. EpCAM
overexpression (TIS >4) and weak expression (TIS 1e4) were
found in 64% (n¼14) and 32% (n¼7) of tumour samples,
respectively. Only 4% (n¼1) lacked EpCAM expression (TIS 0).
We observed a correlation between the EpCAM expression
scores (TIS) of primary tumours and those of synchronous
metastases (p<0.001; ﬁgure 2). Moreover, a correlation of
EpCAM expression in primary tumours and metachronous
metastases was seen (p¼0.003, ﬁgure 3). The degree of concor-
dance between EpCAM overexpression in primary tumour and
metastases was highest in patients with ovarian cancer (n¼8).
In fact, 100% (n¼8) showed concordance in EpCAM over-
expression or non-overexpression. In 71 available patients with
primary colorectal cancer and metastases, the degree of concor-
dance was 76% (n¼54). Fourteen per cent (n¼10) changed the
EpCAM status from overexpression to non-overexpression, and
10% (n¼7) changed the EpCAM status from non-overexpression
to overexpression. Moreover, patients with breast cancer avail-
able for this analyses (n¼20) showed a concordance of 65%
(n¼13). Fifteen per cent (n¼3) changed EpCAM status from
overexpression to non-overexpression and 20% (n¼4) changed
EpCAM status from non-overexpression to overexpression.
DISCUSSION
During recent decades, immunohistochemistry (IHC) has
become a useful adjunctive method in diagnostic histopa-
thology. The development of novel cancer therapies has raised
the demand for accurate measurement of target molecules as
a means to select patients. IHC is easy to perform on a variety of
tumour samples, and therefore it has rapidly become the
predominant method for measuring therapeutic targets in clin-
ical practice. However, comparative immunohistochemical
analysis of antigens such as hormone receptors or Her-2/neu in
different laboratories with the same detection system has led to
discrepant data,
20 21 and some tests have been abandoned (that
is, epidermal growth factor receptor). There are a number of
drawbacks with IHC, the most important of which are lack of
assay standardisation (pre-test variability) and variance in the
interpretation of the immunohistochemical staining (post-test
variability). As such, the interpretation of antigen staining
intensity is a matter of debate, and in some cases not recom-
mended (that is, American Society of Clinical Oncology
hormone receptor testing guidelines).
22
Table 4 EpCAM expression in upper digestive, respiratory tract and (neuro)endocrine cancers
Tumour type (no. of samples)
No EpCAM overexpression* EpCAM overexpression*
No expression
(TIS 0)
Weak expression
(TIS 1e4)
Moderate expression
(TIS 6, 8)
Intense expression
(TIS 9, 12)
n% n% n% n%
Oral cavity cancer, SCC (126) 51 40 48 38 11 9 16 13
Non-small-cell lung cancer (146) 11 7 28 19 36 25 71 49
Small cell lung cancer and other
PDNET (60)
12 20 3 5 18 30 27 45
WDNET (53) 2 4 4 8 2 4 45 84
Differentiated thyroid cancer (88) 2 3 9 10 25 28 52 59
EpCAM expression was determined by immunohistochemistry.
*EpCAM overexpression deﬁned by Gastl et al
3.
EpCAM, epithelial cell adhesion molecule; PDNET, poorly differentiated neuroendocrine tumour; SCC, squamous cell cancer; TIS, total immunostaining score; WDNET, well-differentiated
neuroendocrine tumour.
Table 5 EpCAM expression in metastases of different tumour origin
Tumour type (no. of samples)
No EpCAM overexpression* EpCAM overexpression*
No expression
(TIS 0)
Weak expression
(TIS 1e4)
Moderate expression
(TIS 6, 8)
Intense expression
(TIS 9, 12)
n% n% n % n %
Liver metastases from colorectal cancer (18) 0 0 3 17 0 0 15 83
CNS metastases from breast cancer (15) 1 7 5 33 4 27 5 33
Peritoneal metastases from colon, ovary,
pancreatobiliary and gastric cancer (22)
14 7 3 2 1 0 4 5 4 1 9
Lymph node metastases from breast cancer (5) 2 40 1 20 1 20 1 20
Lymph node metastases from colon cancer (48) 0 0 5 10 4 8 39 81
EpCAM expression was determined by immunohistochemistry.
*EpCAM overexpression deﬁned by Gastl et al
3.
CNS, central nervous system; EpCAM, epithelial cell adhesion molecule; TIS, total immunostaining score.
418 J Clin Pathol 2011;64:415e420. doi:10.1136/jcp.2011.090274
Original articleAchieving reproducible thresholds applicable across laborato-
ries is one of the most difﬁcult challenges of modern IHC.
Correct semiquantitative estimation of the antigen content
requires the setting of cut-off levels between what is to be
considered a positive or negative result. The cut-off between
EpCAM-overexpressing and non-overexpressing samples was
deﬁned by our group taking into account a bimodal distribution
of EpCAM expression scores (TIS) in 205 breast cancer patients
3
and a statistical power-driven disease-free survival analyses
similar to an area under the receiver operating characteristic
curve (AUROC-) analysis.
23 A very similar percentage of
EpCAM-expressing breast cancer samples deﬁned by western
blot analysis has been reported by an independent group.
24
Taking together these observations and all validation studies
that have followed,
4782 5we suggest that this cut-off is prob-
ably the most useful threshold for clinical use. However, it
remains to be determined whether EpCAM expression deﬁned
by IHC predicts therapy response in patients treated with
EpCAM-speciﬁc targeting agents, and whether patients with
weak or even negative EpCAM expression might also beneﬁt
from such treatment approaches. The ﬁrst clinical trial assessing
this issue showed a target-dependent clinical activity of the
adecatumumab antibody in patients with metastastatic breast
cancer.
17 However, validation trials with large patient samples
and adequate EpCAM-expression-based selection are warranted
to clarify this question. In consideration of this fact, we decided
to additionally illustrate four subgroups with different grades of
EpCAM expression (that is, no, low, moderate or intense) to
Figure 1 Comparison between
immunohistochemical epithelial cell
adhesion molecule (EpCAM) expression
in primary breast cancer and
metastases. (A) Invasive ductal
carcinoma with strong EpCAM
expression (total immunostaining score
(TIS) 12). (B) Brain metastases from the
same patient showing strong EpCAM
expression (TIS 12). (C) Invasive lobular
carcinoma with weak EpCAM
expression (TIS 3); arrows: normal
breast ducts showing EpCAM
expression. (D) Peritoneal metastases
from the same patient showing weak
EpCAM expression (TIS 3).
Figure 2 Regression analysis of the correlation of epithelial cell
adhesion molecule (EpCAM) expression between primary tumours and
synchronous metastases. TIS, total immunostaining score.
Figure 3 Regression analysis of the correlation of epithelial cell
adhesion molecule (EpCAM) expression between primary tumours and
metachronous metastases. TIS, total immunostaining score.
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Original articlefavour adequate prospective evaluation of the predictive value of
EpCAM expression in clinical trials and observational studies.
Adenocarcinomas usually revealed high EpCAM expression
scores. Exceptions were hepatocellular carcinomas, breast cancer
and renal cell cancer. In some cases, the EpCAM expression
proﬁle might indicate a particular biological behaviour of the
tumour. In fact, invasive lobular breast cancer frequently
showed either no or weak EpCAM expression. Lobular carci-
nomas tend to metastasise later than invasive ductal carcinomas
and spread to unusual locations such as the peritoneum
(ﬁgure 1D), meninges and gastrointestinal tract.
26 Since EpCAM
appears to be important for detection of circulating tumour cells,
the evaluation of EpCAM expression in primary breast cancer is
becoming fundamental.
27 Other malignant tumours that
frequently lack EpCAM expression are urothelial carcinomas and
squamous cell cancer. In these cases, the expression of malignant
cells reﬂects the expression of their benign counterparts in
healthy tissues.
Important information has been derived from the evaluation
of EpCAM expression in metastases. We observed that EpCAM
expression in synchronous and metachronous metastases corre-
lated with that of the primary tumour. Thus, evaluation of
EpCAM expression in patients treated with EpCAM-speciﬁc
antibodies might be performed on archived tumour samples
obtained at the time of primary diagnosis or alternatively on
metastases. However, since we observed that concordance of
EpCAM status between primary tumour and metastases is not
always assured, EpCAM IHC should be preferentially performed
on metastatic lesions, if available. Taking the results together, we
suggest performing EpCAM IHC particularly in patients with
breast cancer, renal cell cancer, squamous cell carcinomas,
hepatocellular carcinoma and urothelial cancer when treatment
with EpCAM-speciﬁc antibodies is planned.
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Take-home messages
< The antibody catumaxomab has been approved for intraper-
itoneal use in cancer patients with epithelial cell adhesion
molecule (EpCAM)-positive tumours.
< EpCAM is expressed in certain human cancers and its
expression in metastases frequently reﬂects that of primary
tumours.
< If treatment with EpCAM-speciﬁc antibodies (that is,
catumaxomab) is planned in patients with cancer, we
suggest evaluation of EpCAM expression by immunohisto-
chemistry on primary tumours or preferentially on metastases.
This evaluation should be performed particularly in patients
with breast cancer, renal cell cancer, squamous cell
carcinomas, hepatocellular carcinomas and urothelial cancer.
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